From: The epigenetic implication in coronavirus infection and therapy
Epigenetic modification | Virus infection | Target | Functional outcome |
---|---|---|---|
Histone methylation | H3N2 influenza A | H3K4 | Inhibition of the initiation of the host innate immune response [55] |
SARS-CoV | H3K4me | Promotion of active transcription and ISG expression [16] | |
H3K4me3 | |||
H1N1 | H3K4me | ||
MERS-CoV | H3K27me3 | Down-regulation/inactivation of ISGs [16, 57, 63] and development of antagonistic mechanism to target the IFN innate immune response [59] | |
H3K4me3 | |||
HSV | – | ||
H5N1-Vn1203 | H3K27me3 | ||
HIV-1 | – | ||
Histone acetylation | Adenovirus (Ad) E1A | H3K9ac | Interference with epigenetic functions and global immune function [55] |
H3K27ac | |||
DNA methylation | SARS-CoV | – | Delay/offset of pathogen recognition and modulation of ISG expression levels [16] |
MERS-CoV | – | Loss of antigen-presentation molecules [58] | |
HSV | – | Delay/offset of pathogen recognition and modulation of ISG expression levels [16] | |
H5N1-Vn1203 | – | Loss of antigen-presentation molecules [58] | |
HIV-1 | – | Delay/offset of pathogen recognition and modulation of ISG expression levels [16] | |
HCV | – | Interference with global immune function [56] | |
RNA methylation | KSHV | m6A/m6Am | Mediation of the stability of the viral transcripts [70] |
SARS-CoV | 5mC | Modulation of the structure and the viral replication [67, 68] | |
HBV | m6A | Regulation of gene expression and reverse transcription; transcript destabilization [69] |